1. Scrip
  2. >>Therapy Areas
  3. >>Genitourinary

Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders

Recently Appointed CEO Richard Francis Outlines Development Path

 
• By John Davis

Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.

Emerging Company Profile Regular column feature image Version 2

The UK’s Purespring Therapeutics is one of the first gene therapy companies to focus on diseases of the kidney, and with ex-Sandoz CEO Richard Francis appointed Purespring’s CEO from 1 February, the emerging biotech is expected to move forward quickly with therapeutic candidates that it aims to take right to the market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

Still Looking For A Gene Therapy Hit, Syncona Backs Purespring In IgA Nephropathy Market

 
• By Andrew McConaghie

Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.

REGENCY Dandy for Roche In Lupus Nephritis

 
• By Elizabeth Cairns

Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.    

AstraZeneca Believes Size Matters In Amyloidosis

 
• By Elizabeth Cairns

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.    

Pfizer And Flagship’s Quotient To Seek Out New Heart And Kidney Drugs

 
• By Andrew McConaghie

The big pharma’s second selection in the alliance shows novel cardiovascular therapies are high on its priority list

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.